Previously Treated or Remitted Posttraumatic Stress Disorder and Renewed Military Trauma Exposure: Evidence Gaps and a Provisional Fitness-for-Duty Framework

Mil Med. 2026 Sep 21:usag431. doi: 10.1093/milmed/usag431. Online ahead of print.

ABSTRACT

INTRODUCTION: Military clinicians may be required to assess personnel with previously treated or remitted posttraumatic stress disorder (PTSD) for return to duty, deployment, weapons-related responsibilities, or other safety-sensitive assignments involving renewed trauma exposure. Direct evidence after verified remission and unrestricted military return is sparse. This review does not develop a new PTSD screening instrument or actuarial fitness score. Its aim is to synthesize the available evidence and translate it into a provisional, structured fitness-for-duty assessment and documentation framework.

MATERIALS AND METHODS: A structured narrative review used targeted PubMed/MEDLINE searches from January 2000 through July 22, 2026. Search domains included prior or remitted PTSD, subsequent trauma and deployment, recurrence, treatment outcomes, comorbidity, sleep, moral injury, occupational functioning, screening, safety outcomes, and heart rate variability. Four reviewer-directed update searches yielded 220 unique records after deduplication. Military and veteran studies were prioritized. Evidence was classified as direct, near-direct, indirect, or contextual, and overlapping cohorts were treated as publication families rather than independent samples.

RESULTS: No cohort followed independently verified sustained PTSD remission through unrestricted military clearance or redeployment and prospectively measured recurrence, weapon incidents, duty failure, medical evacuation, or other safety outcomes. An active-duty case-control study documented 26 women who returned to full duty after PTSD-related limited duty, but its design did not permit estimation of a return-to-duty rate or later adverse outcomes. Two reports from the same 282-person active-duty residential-treatment cohort showed that only 32.6% achieved a clinically significant PCL-M reduction, residual symptoms remained frequent, and greater symptom improvement predicted longer military retention; treatment response was not remission. Among 523,626 active-duty Sailors and Marines, 83.3% of personnel diagnosed with PTSD had at least 1 examined comorbidity. Veteran data indicated that severe violence was associated with PTSD plus alcohol misuse rather than PTSD alone after adjustment. Deployment-related late-onset and chronic symptom trajectories were associated with suicidal ideation, supporting delayed reassessment. In a large VA cohort, study-defined symptomatic remission was associated with lower suicide mortality. Screening instruments and heart rate variability may support monitoring, but neither provides a validated military fitness threshold.

CONCLUSIONS: Treated or remitted PTSD should be neither an automatic permanent contraindication nor a clinically neutral history. Fitness assessment should distinguish treatment response from sustained clinical and functional remission and separately evaluate residual symptoms, psychiatric comorbidity, sleep, substance use, suicidality, anger and impulse control, moral injury, occupational function, and task demands. The proposed framework is a provisional, non–actuarial assessment and documentation aid, not a new PTSD screening test or validated prediction rule. Prospective studies following personnel from independently verified remission through return to unrestricted duty are required before quantitative postremission risk estimates can be established.

PMID:42766696 | DOI:10.1093/milmed/usag431